John W. Childs

Mr. John W. Childs is a Director of Kleo Pharmaceuticals. He serves as the Chairman and Partner of J.W. Childs Associates, L.P., a private equity firm. He co-founded J.W. Childs Associates in 1995. Prior to founding J.W. Childs Associates, Mr. Childs was Senior Managing Director of the Thomas H. Lee Company from 1991 to 1995. In this capacity, he had broad responsibilities for originating, analyzing, negotiating and managing leveraged buyout transactions for the THL funds. For seventeen years prior to joining THL, Mr. Childs was with the Prudential Insurance Company of America where he held various executive positions in the investment area, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. He is currently Chairman of Sunny Delight and a director of Kosta Browne, Esselte, Mattress Firm, WS Packaging and SIMCOM. Prior to its sale, he was Chairman of the Board of CHG Healthcare Services. Mr. Childs has a B.A. from Yale University and a M.B.A. from Columbia University.


Declan Doogan, M.D.

Dr. Doogan is the Chairman and a Director of Kleo Pharmaceuticals. He is a seasoned drug development executive and life sciences investor with more than 30 years experience in the global pharmaceutical industry. He joined Pfizer in 1982, where he held a number of senior positions in R&D in the USA, UK and Japan. Dr. Doogan was the clinical development head for what was to become ZOLOFT, an important antidepressant and one of the top selling products in the world.  He retired from Pfizer in 2007 as the Senior VP Head of World Drug Development. Subsequently Dr. Doogan was Head of R&D at Amarin where, along with the CEO, he raised $100m to fund the reorganization and portfolio realignment leading to completion of a Phase III program and NDA approval for Vascepa (icosapent ethyl) for elevated triglycerides. During his career Dr. Doogan has engaged in activities to promote excellence in pharmaceutical medicine and sits on the Boards of several biotechnology companies.


Charles G. Drake, M.D., Ph.D.

Dr. Charles George Drake is a Director of Kleo Pharmaceuticals. He is a professor of oncology, urology and immunology at the Johns Hopkins School of Medicine. He also serves as Co-Director of the Prostate Cancer Multidisciplinary Clinic. His areas of expertise include immunotherapy and the diagnosis and treatment of cancers of the prostate, kidney, bladder and testes. Dr. Drake graduated with a B.S. in electrical engineering and M.S. in biomedical engineering from Rutgers University. He then received a Ph.D. in immunology from the National Jewish Center for Immunology, and in 1997 completed an M.D. at the University of Colorado Health Sciences Center. He conducted an internal medicine residency on the Osler Service at Johns Hopkins, and in 2002 he completed a fellowship in medical oncology, also at Johns Hopkins. He joined the Johns Hopkins faculty as an assistant professor in 2002.


Alex Goor

Alex Goor has spent 20 years building electronic financial markets. Firms he has helped lead and create, both from a technical and management leadership vantage, have been sold to ICE/NYSE, Ameritrade, the NASDAQ, Nomura, and leading private equity firms, including Silver Lake and Bain Capital.

Alex began his career as the Chief Strategy Officer of Datek Online Holdings Corporation, where he supervised all business development efforts. Datek offered online brokerage services to almost 1 million retail clients, among other services.  After Datek, Alex became co-CEO and CIO of Instinet, an institutional agency brokerage servicing the largest global asset managers, where in 17 months he and his team increased the firm’s value 6 times. The company was purchased in a management buy-out in December 2005 for $207 million and sold 17 months later for $1.3 billion.

From 2010 to 2015, Alex was the Chief Information Officer of Interactive Data Corporation (IDC), a Silver Lake and Warburg Pincus portfolio company.  In 2015, the group sold IDC to ICE/NYSE for $5.3 billion, having tripled their equity investment of $1.3 billion. IDC is the preeminent provider of pricing for fund managers with as much as 98% market share in critical markets. Among Alex’s accomplishments in this role was to create the technical capability to provide real-time pricing for millions of global fixed income securities, a marked improvement from end-of-day pricing which was, until this advent, the norm. In addition, he was able to leverage new technologies to create an integrated platform that reduced costs. In this role as Head of Technology, 1,000 people, roughly 40% of the employees, and 50% of the costs reported up to Alex.

Alex currently is a trustee of Saint Ann’s School in Brooklyn and on the boards of Dealogic, a Carlyle company, and Insurity, a TA Associates and General Atlantic company.  He has served as a director on the Board of Directors of BondDesk. He received his Bachelor of Arts with a concentration in Mathematics from Columbia University in 1995, Phi Beta Kappa and Magna Cum Laude. Alex is an accomplished pianist and studied for years at The Juilliard School of Music in New York before changing direction to become a pioneer of financial technology. Alex lives in New York with his wife and two children.



Doug is CEO of Kleo Pharmaceuticals.  He has 20 years’ experience in drug development.  He was the Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at BMS until October 2016.  He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GSK. He started his career at DuPont Pharmaceuticals in 1997.  He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School.  Doug also serves on the Board of Directors of Celleron Therapeutics.


Roy Prieb

Roy Prieb is the COO/CFO and co-founder of Kleo Pharmaceuticals. He is a technology entrepreneur with over 15 years experience in business strategy, development, and operations. Roy has helped launch, fund, and grow several digital media ventures including Saaspire, Kellogg Media Group,, and Earlier in his career, he was a consultant with The Boston Consulting Group. He received his B.A. from Harvard University and M.B.A. from Wharton Business School.


Observers & Advisors


Gregory H. Bailey, M.D.

Dr. Bailey has spent the last fifteen years as an entrepreneur, executive and financier in the health care sector. He is currently Chairman of the Board at Portage Biotech Inc. and has served on the Board of Directors for 16 public companies. He is a former director and financier of Medivation Inc. (MDVN: NASDAQ) and co-founder of Ascent Healthcare Solutions, VirnetX Inc internet security (VHC: AMEX) and Duramedic Inc., a medical products company. Prior posts within the investment and financial services sector included serving as Managing Director of Gilford Securities Inc., Managing Director of Knightsford Bank Corp, Senior Managing Director positions at Viscogliosi Brothers and the LXV Prosperity Fund, founder and General Manager of the ABN Private Equity Fund, co-foundeer of EuroAmerican Mercantile Bancorp, and co-founder and CEO of V-Fund Investments, Ltd. Dr. Bailey received his Medical Degree from the University of Ontario before practicing for ten years as an emergency room Physician.


Vlad Coric, M.D.

Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), and YERVOY® (Ipilimumab; anti-CTLA-4), . Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.


Christopher Eklund

Mr. Eklund is a Managing Director at J.W. Childs Associates focusing on venture capital investments.  The Childs venture portfolio includes investments in BioHaven Pharmaceuticals (NYSE: BHVN), Kleo Pharmaceuticals, Melinta Therapeutics, Omax Health, Inc, Stemedica Cell Technologies and Basin Holdings.  Prior to joining J.W. Childs, Mr. Eklund was Managing Director/Head of Corporate Strategy and Mergers & Acquisitions at New York Life Investment Management. He was a Director at Berkshire Capital Corporation; Furman Selz LLC and Merrill Lynch & Co. He is currently Chairman of Omax Health, Inc.  Mr. Eklund received an A.B. from Harvard College and an M.B.A. from Harvard Business School


David A. Lewin, Ph.D.

Observer and Representative of Yale University Office of Cooperative Research. Dr. Lewin has more than ten years of licensing and marketing experience in life sciences with Yale’s Office of Cooperative Research (OCR) and has spent more than 17 years successfully managing scientific-based business alliances with pharmaceutical leaders in the U.S., Europe and Asia. He has scientific expertise in pharmaceuticals, biomarkers, cell biology, genomics and proteomics in many disease areas as well as clinical biomarker discovery, development, validation and clinical implementation experience. Dr. Lewin has been instrumental in establishing and growing new ventures arising from Yale technology, including Kolltan Pharmaceuticals, NovaTract, New Haven Pharmaceuticals, Eli Nutrition, and Biohaven Pharmaceuticals. Prior to his work at OCR, Dr. Lewin was a group leader for CuraGen Corporation in collaborative research/alliance management and biomarker discovery and development. Dr. Lewin holds a B.A. in Biochemistry and Cell Biology from the University of California San Diego and a Ph.D. in Cell Biology from Yale (Mellman Lab).


David Spiegel, M.D., PH.D.

David is the Chief Scientific Advisor and co-founder of Kleo Pharmaceuticals. He is a Professor of Chemistry and Pharmacology at Yale University where he heads the Spiegel Research Group. He has co-authored over 40 peer-reviewed publications and is an inventor with over a dozen patents, including those that underlie Kleo's ARM and SyAM platforms. He has been recognized with various awards and honors, including the NIH Director's New Innovators Award, the Ellison Medical Foundation New Scholar Award in Aging Research, the Bill and Melinda Gates Foundation Grand Challenges Explorations Award, an Alfred P. Sloan Foundation Fellowship, an Arthur C. Cope Early Career Scholars Award, and others.

20130513_CTinnovations_022 crop.jpg

Daniel Wagner

Dan is responsible for evaluating investment opportunities, structuring new investments and monitoring portfolio companies at Connecticut Innovations.  He contributes to CI’s expertise in biotech with more than 10 years in the industry. He was previously employed by CuraGen Corporation where Dan held a variety of scientific and operational management positions in research and development, technology assessment and implementation of next-generation scientific technologies in support of CuraGen’s development of its protein, antibody-drug conjugates and small-molecule therapeutics.  Dan received a B.S. in Biology from the University of Dayton and from Quinnipiac University, a M.H.S. in Biomedical Sciences and a M.B.A.